Illustrative image (Source: VNA)
Hanoi (VNA) - Merger andacquisition (M&A) activities between domestic and foreign pharmaceuticalcompanies are being seen in both production and distribution.
Most recently, Japan’s AskaPharmaceutical signed an agreement to acquire a 24.9 percent stake inVietnamese pharmaceutical company Hataphar, formally theHa Tay Pharmaceutical JSC.
Other majornames in global pharmaceuticals are present in Vietnam, including the AbbottGroup from the US and the Adamed Group from Poland.
In thecontext of COVID-19, pharmaceutical companies are expected to enjoy substantialbenefits and breakthroughs into the future.
Thegreatest challenge at the moment is that 80-90 percent of raw materials areimported, primarily from China and India. In the first two months of this year,when the pandemic first broke out, material imports from the two countries fell30 percent and 25.8 percent, respectively, to 27.2 million USD and 9.4 millionUSD.
Marketresearchers IBM said the size of Vietnam’s pharmaceutical industry could reach7.7 billion USD in 2021 and 16.1 billion USD in 2026, while researchers IMSHealth forecast that per capita spending on pharmaceuticals in the country wouldrise to 50 USD this year./.
